Mario Matta

Mario Matta

Auto-generated profile, based on publicly available information

Mario Matta

A.O.U. San Giovanni Battista Molinette, Division of Cardiology, Cardiovascular and Thoracic Department , Turin , Italy

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
Matteo AnselminoMatteo Anselmino
Matteo Anselmino
MMMario Matta
Mario Matta
FDFabrizio D’aScenzo
Fabrizio D’aScenzo
TBT. Jared Bunch
T. Jared Bunch
RSRichard J. Schilling
Richard J. Schilling
FGFiorenzo Gaita
Fiorenzo Gaita
Background—: Catheter ablation of atrial fibrillation (AFCA) is an established therapeutic option for rhythm control in symptomatic patients. Its efficacy and safety among patients with left ventricular systolic dysfunction is based on small populations, and data concerning long-term outcome are limited. We performed this meta-analysis to assess safety and long-term outcome of AFCA in patients with left ventricular systolic dysfunction, to evaluate predictors of recurrence and impact on left ventricular function. Methods and Results—: A systematic review was conducted in MEDLINE/PubMed and Cochrane Library. Randomized controlled trials, clinical trials, and observational studies including patients with left ventricular systolic dysfunction undergoing AFCA were included. Twenty-six studies were selected, including 1838 patients. Mean follow-up was 23 (95% confidence interval, 18–40) months. Overall complication rate was 4.2% (3.6%–4.8%). Efficacy in maintaining sinus rhythm at follow-up end was 60% (54%–67%). Meta-regression analysis revealed that time since first atrial fibrillation ( P =0.030) and heart failure ( P =0.045) diagnosis related to higher, whereas absence of known structural heart disease ( P =0.003) to lower incidence of atrial fibrillation recurrences. Left ventricular ejection fraction improved significantly during follow-up by 13% ( P <0.001), with a significant reduction of patients presenting an ejection fraction <35% ( P <0.001). N-terminal pro-brain natriuretic peptide blood levels decreased by 620 pg/mL ( P <0.001). Conclusions—: AFCA efficacy in patients with impaired left ventricular systolic function improves when performed early in the natural history of atrial fibrillation and heart failure. AFCA provides long-term benefits on left ventricular function, significantly reducing the number of patients with severely impaired systolic function.

23 October 2015 in EP Europace
Verified
Journal Article
Closed access
PDF file
Matteo AnselminoMatteo Anselmino
Matteo Anselmino
MMMario Matta
Mario Matta
FDFabrizio D'AScenzo
Fabrizio D'AScenzo
CPCarlo Pappone
Carlo Pappone
VSVincenzo Santinelli
Vincenzo Santinelli
FGFiorenzo Gaita
Fiorenzo Gaita
Aims Diabetes mellitus (DM) and atrial fibrillation (AF) share pathophysiological links, as supported by the high prevalence of AF within DM patients. Catheter ablation of AF (AFCA) is an established therapeutic option for rhythm control in drug resistant symptomatic patients. Its efficacy and safety among patients with DM is based on small populations, and long-term outcome is unknown. The present systematic review and meta-analysis aims to assess safety and long-term outcome of AFCA in DM patients, focusing on predictors of recurrence. Methods and results A systematic review was conducted in MEDLINE/PubMed and Cochrane Library. Randomized controlled trials, clinical trials, and observational studies including patients with DM undergoing AFCA were screened and included if matching inclusion and exclusion criteria. Fifteen studies were included, adding up to 1464 patients. Mean follow-up was 27 (20–33) months. Overall complication rate was 3.5 (1.5–5.0)%. Efficacy in maintaining sinus rhythm at follow-up end was 66 (58–73)%. Meta-regression analysis revealed that advanced age (P < 0.001), higher body mass index (P < 0.001), and higher basal glycated haemoglobin level (P < 0.001) related to higher incidence of arrhythmic recurrences. Performing AFCA lead to a reduction of patients requiring treatment with antiarrhythmic drugs (AADs) from 55 (46–74)% at baseline to 29 (17–41)% (P < 0.001) at follow-up end. Conclusions Catheter ablation of AF safety and efficacy in DM patients is similar to general population, especially when performed in younger patients with satisfactory glycemic control. Catheter ablation of AF reduces the amount of patients requiring AADs, an additional benefit in this population commonly exposed to adverse effects of AF pharmacological treatments.

25 July 2012 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
Matteo AnselminoMatteo Anselmino
Matteo Anselmino
SGStefano Grossi
Stefano Grossi
MSMarco Scaglione
Marco Scaglione
DCDavide Castagno
Davide Castagno
FBFrancesca Bianchi
Francesca Bianchi
FGFiorenzo Gaita
Fiorenzo Gaita

8 February 2016 in EP Europace
Verified
Journal Article
Closed access
PDF file
Matteo AnselminoMatteo Anselmino
Matteo Anselmino
MMMario Matta
Mario Matta
DCDavide Castagno
Davide Castagno
CGCarla Giustetto
Carla Giustetto
FGFiorenzo Gaita
Fiorenzo Gaita
Catheter ablation of atrial fibrillation (AFCA) is a widely recommended treatment for symptomatic atrial fibrillation (AF) patients refractory to pharmacological treatment. Catheter ablation of AF is becoming a therapeutic option also among patients with chronic heart failure (CHF), on top of optimal medical treatment, being this arrhythmia related to a higher risk of death and/or symptom's worsening. In fact, in this setting, clinical evidences are continuously increasing. The present systematic review pools all published experiences concerning AFCA among CHF patients, or patients with structural cardiomyopathies, in order to summarize procedural safety and efficacy in this specific population. Moreover, the effects of AFCA on functional class and quality of life and the different procedural protocols available are discussed. The present work, therefore, attempts to provide an evidence-based clinical perspective to optimize clinical indication and tailor procedural characteristics and endpoints to patients affected by CHF referred for AFCA.

1 December 2015 in Journal of Cardiovascular Medicine
Verified
Journal Article
Closed access
Matteo AnselminoMatteo Anselmino
Matteo Anselmino
ABAlberto Battaglia
Alberto Battaglia
CGCristina Gallo
Cristina Gallo
SGSebastiano Gili
Sebastiano Gili
MMMario Matta
Mario Matta
FGFiorenzo Gaita
Fiorenzo Gaita
Atrial fibrillation is the most common supraventricular arrhythmia. Its prevalence increases with age and preferentially affects male patients. Over 75 years of age, however, female patients being more prevalent, the absolute number of patients affected is similar between sexes. Despite this, few data are available in the literature concerning sex-related differences in atrial fibrillation patients. The present systematic review therefore considers comorbidities, referring symptoms, quality of life, pharmacological approaches and trans-catheter ablation in female rather than in male atrial fibrillation patients in search of parameters that may have an impact on the treatment outcome. In brief, female atrial fibrillation patients more commonly present comorbidities, leading to a higher prevalence of persistent atrial fibrillation; moreover, they refer to hospital care later and with a longer disease history. Atrial fibrillation symptoms relate to low quality of life in female patients; in fact, atrial fibrillation paroxysm usually presents higher heart rate, leading to preferentially adopt a rate rather than a rhythm-control strategy. Female atrial fibrillation patients present an increased risk of stroke, worsened by the lower oral anticoagulant prescription rate related to the concomitant higher haemorrhagic risk profile. Trans-catheter ablation is under-used in female patients and, on the contrary, they are more commonly affected by anti-arrhythmic drug side effects.

18 August 2019 in Medicina
Verified
Journal Article
Open access
PDF file
ABAndrea Ballatore
Andrea Ballatore
MMMario Matta
Mario Matta
ASAndrea Saglietto
Andrea Saglietto
PDPaolo Desalvo
Paolo Desalvo
PBPier Paolo Bocchino
Pier Paolo Bocchino
Matteo AnselminoMatteo Anselmino
Matteo Anselmino
Atrial Fibrillation (AF) may be diagnosed due to symptoms, or it may be found as an incidental electrocardiogram (ECG) finding, or by implanted devices recordings in asymptomatic patients. While anticoagulation, according to individual risk profile, has proven definitely beneficial in terms of prognosis, rhythm control strategies only demonstrated consistent benefits in terms of quality of life. In fact, evidence collected by observational data showed significant benefits in terms of mortality, stroke incidence, and prevention of cognitive impairment for patients referred to AF catheter ablation compared to those medically treated, however randomized trials failed to confirm such results. The aims of this review are to summarize current evidence regarding the treatment specifically of subclinical and asymptomatic AF, to discuss potential benefits of rhythm control therapy, and to highlight unclear areas.